Result of Retail Offer

Arecor Therapeutics plc (AIM: AREC), a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases, is pleased to announce that, further to the announcement made at 3.00 p.m. on 30 September 2026, the Retail Offer closed at 12.00 p.m. today and was oversubscribed.

Following the closing of the Retail Offer, 191,176 Retail Offer Shares will be issued at a price of 68 pence per Retail Offer Share, raising gross proceeds of approximately £0.13 million.

Accordingly, following the issue of the 7,352,941 Placing Shares on 6 October 2026, a total of 7,544,117 new Ordinary Shares will be issued pursuant to the Fundraising, resulting in aggregate gross proceeds of approximately £5.13 million for the Company.

Capitalised terms used in this announcement shall, unless defined in this announcement or unless the context provides otherwise, bear the same meaning ascribed to such terms in the Company’s first announcement released on 30 September 2026 (RNS Number 8641W).

Admission and Dealings

Completion of the Retail Offer is conditional upon the Retail Offer Shares being admitted to trading on AIM.

An application has been made to the London Stock Exchange for the Retail Offer Shares to be admitted to trading on AIM. It is anticipated that Second Admission will become effective and that dealings in the Retail Offer Shares will commence on AIM at 8.00 a.m. on 9 October 2026.

Total Voting Rights

Following Second Admission, the Company's issued share capital will consist of 45,300,718 Ordinary Shares, each carrying the right to one vote. The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of Ordinary Shares and voting rights in the Company following Second Admission will be 45,300,718.